BioCentury
ARTICLE | Financial News

ThromboGenics slides on Jetrea sales, flat guidance

August 30, 2013 11:58 PM UTC

ThromboGenics N.V. (Euronext:THR) shed EUR 5.12 (18%) to EUR 22.93 on Friday after reporting 1H13 U.S. sales of ophthalmic drug Jetrea ocriplasmin that missed Street estimates and guiding to a similar sales figure in 2H13. ThromboGenics, which launched Jetrea in the U.S. in January to treat symptomatic vitreomacular adhesion (VMA), reported EUR 12.5 million ($16.3 million) in U.S. Jetrea sales in the half, missing the Street's estimate of EUR 15 million ($19.5 million). On a conference call to discuss its 1H13 earnings, the company said it does not expect major changes to Jetrea's uptake in the U.S. in the near term. The Street was expecting EUR 24 million ($31.2 million) in 2H13 Jetrea sales. ...